Microbot Medical Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Microbot Medical Inc (MBOT) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Microbot Medical Inc vs Its Competitors
- Profitability: Its -2,334.9% net margin compares with -4.5% for the peer group.
- Scale: Microbot Medical Inc ranks #127 of 246 companies by market capitalization in the Medical Equipment & Supplies industry, holding 0.0% of industry market cap.
- Peer revenue share: Microbot Medical Inc accounted for 0.1% of combined revenue among its tracked peer group.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
MBOT Sales vs. its Competitors, Q2 2026
With a net margin of -2,334.85 %, Microbot Medical Inc reported lower profitability than its competitors (-4.47 %).
Microbot Medical Inc generated 0.10 % of the combined sales of its peer group.
API endpoints for this dataset
Microbot Medical Inc vs. its Competitors, Q2 2026
Net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Microbot Medical Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Microbot Medical Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Microbot Medical Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (9) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Microbot Medical Inc's competitor groups requires a Commercial License.
Microbot Medical Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Microbot Medical Inc | - | - | - | Yes |
| Competitors combined (5) | ||||
| High-Confidence Competitors (1) | - | |||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
MBOT Stock Performance relative to its Competitors
MBOT Stock Performance relative to High-Confidence Competitors
MBOT Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Myomo Inc | 282.9% | Outperformed |
| 2 | Irhythm Holdings Inc | 282.9% | Outperformed |
| 3 | Pavmed Inc | 282.9% | Outperformed |
| 4 | Sanuwave Health Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Microbot Medical Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Microbot Medical Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Microbot Medical Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Microbot Medical Inc |
74.55 | - |
 Irhythm Holdings Inc |
2,967.79 | 825.70 |
 Myomo Inc |
51.66 | 44.24 |
 Sanuwave Health Inc |
18.84 | 43.90 |
 Pavmed Inc |
9.85 | 0.13 |
 Vycor Medical Inc |
1.74 | 1.81 |
| SUBTOTAL | 3,124.42 | 915.78 |
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Microbot Medical Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Microbot Medical Inc's Competitors Named by the Company
Competitive relationships identified from Microbot Medical Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Nanoflex Robotics | Company report | 85% |
| Endoways | Company report | 85% |
| UAB Inovatyvi medicina | Company report | 85% |
| Robocath | Company report | 85% |
| Siemens Healthineers | Company report | 85% |
| LN Robotics | Company report | 85% |
| Corindus Vascular Robotics | Company report | 85% |
| Siemens Healthineers | Company report | 85% |
| Pavmed Inc | Company report | 85% |
| Myomo Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Microbot Medical Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Microbot Medical Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Sanuwave Health Inc | Reportable 100.00 % |
| Vycor Medical Inc | Vycor Medical Inc 95.93 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Microbot Medical Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Microbot Medical Inc | 75 | - | -379,977 |
| Irhythm Holdings Inc | 2,968 | 344,043 | -5,811 |
| Myomo Inc | 52 | 226,880 | -74,398 |
| Sanuwave Health Inc | 19 | 798,236 | 260,945 |
| Pavmed Inc | 10 | 3,073 | -400,732 |
| Vycor Medical Inc | 2 | 258,210 | -8,561 |
| PEERS TOTAL | 3,050 | 339,429 | -11,339 |
Microbot Medical Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Vycor Medical Inc | US 99.66 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Microbot Medical Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 218 companies in Microbot Medical Inc's industry classification, broader than the peer set above. Market cap in millions of $.Microbot Medical Inc ranks #127 of 218 companies by market capitalization in its industry, holding 0.01 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 616, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Intuitive Surgical Inc | 161,785 | 13.52 % |
| 2 | Medtronic Plc | 130,823 | 10.94 % |
| 3 | Stryker Corp | 125,786 | 10.51 % |
| 4 | 3m Company | 96,722 | 8.09 % |
| 5 | Boston Scientific Corporation | 1,234 | 5.2% |
| 6 | Edwards Lifesciences Corporation | 1,234 | 5.2% |
| 7 | Becton Dickinson And Company | 1,234 | 5.2% |
| 8 | Alcon inc | 1,234 | 5.2% |
| 9 | Resmed Inc | 1,234 | 5.2% |
| 10 | Medline Inc | 1,234 | 5.2% |
| 127 | Microbot Medical Inc | 75 | 0.01 % |
Market cap and industry share for the rest of Microbot Medical Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-06.
Microbot Medical Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 122 | Vivani Medical Inc | 93 | -25.85 % |
| 123 | Lakeland Industries Inc | 89 | -46.20 % |
| 124 | Outset Medical Inc | 79 | -67.75 % |
| 125 | Neuraxis Inc | 76 | 143.31 % |
| 126 | Polypid Ltd | 1,234 | 12.3% |
| 127 | Microbot Medical Inc | 75 | -48.36 % |
| 128 | Envoy Medical Inc | 1,234 | 12.3% |
| 129 | Lucid Diagnostics Inc | 1,234 | 12.3% |
| 130 | Hyperfine Inc | 1,234 | 12.3% |
| 131 | Electrocore Inc | 1,234 | 12.3% |
| 132 | Nutriband Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Microbot Medical Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-06. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Microbot Medical Inc's Valuation vs Competitive Position
Valuation multiples vs the Medical Equipment & Supplies industry average (342 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Equipment & Supplies industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 37.9x | - |
| EV / EBITDA | - | 18.1x | - |
| P/B | 1.8x | 4.6x | -2.8x |
| Return on Equity | -21.87 % | industry aggregate | -33.85 % |
| Return on Invested Capital | -12.32 % | -6.82 % (avg) | -5.50 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Microbot Medical Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2017 | 2018 | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - |
| Return on Invested Capital | -27.15 % | -27.74 % | -25.94 % | -16.50 % | -79.25 % | -67.86 % | -118.49 % | -13.64 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Microbot Medical Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Microbot Medical Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.8% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Microbot Medical Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 616 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Microbot Medical Inc's dedicated Suppliers and Customers pages, not here.
Microbot Medical Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Microbot Medical Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Microbot Medical Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 33.9 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (40.00 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Microbot Medical Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Microbot Medical Inc | 6.08 | 22.75 | - |
| Irhythm Holdings Inc | 1.96 | 4.50 | 4.18 |
| Myomo Inc | 1.37 | 2.68 | 0.97 |
| Sanuwave Health Inc | 0.53 | 1.21 | - |
| Pavmed Inc | 0.46 | 0.58 | 0.31 |
| Vycor Medical Inc | 0.03 | 0.13 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Microbot Medical Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Microbot Medical Inc | Q2 2026 | - | - |
| Irhythm Holdings Inc | Q2 2026 | +20.6 % | - |
| Myomo Inc | Q2 2026 | +33.8 % | - |
| Sanuwave Health Inc | Q2 2026 | -4.2 % | - |
| Pavmed Inc | Q2 2026 | +135.7 % | - |
| Vycor Medical Inc | Q2 2026 | -15.7 % | - |
| PEERS TOTAL | +20.0 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Microbot Medical Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Microbot Medical Inc | Q2 2026 | - | +1,477.8 % |
| Irhythm Holdings Inc | Q2 2026 | +15.0 % | +30.8 % |
| Myomo Inc | Q2 2026 | +8.7 % | -93.8 % |
| Sanuwave Health Inc | Q2 2026 | +4.9 % | -58.8 % |
| Pavmed Inc | Q2 2026 | +197.6 % | +62.5 % |
| Vycor Medical Inc | Q2 2026 | -9.0 % | - |
Microbot Medical Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Microbot Medical Inc | - | - | - |
| Irhythm Holdings Inc | - | - | - |
| Myomo Inc | - | - | - |
| Sanuwave Health Inc | 39.15% | 91.81% | - |
| Pavmed Inc | - | - | - |
| Vycor Medical Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Microbot Medical Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Microbot Medical Inc | - | - |
| Irhythm Holdings Inc | - | 3.59 |
| Myomo Inc | - | 1.17 |
| Sanuwave Health Inc | 2.21 | 0.43 |
| Pavmed Inc | - | 78.15 |
| Vycor Medical Inc | - | 0.96 |
| PEERS AVERAGE | - | 3.41 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.